Hepatitis C

What is Hepatitis C?

Hepatitis C is a viral infection that primarily affects the liver, caused by the hepatitis C virus (HCV). The infection can be acute (short-term) or chronic (long-term), with chronic hepatitis C being the more serious form that can lead to liver damage over decades. An estimated 58 million people worldwide have chronic hepatitis C, making it one of the leading causes of liver disease globally. The condition often remains silent for years, earning it the nickname “silent epidemic,” as many people are unaware they are infected until significant liver damage has occurred.

Key statistics

Global prevalence:	58 million people with chronic hepatitis C
Annual deaths:	Approximately 290,000 deaths per year
Peak infection rates:	Baby boomers (born 1945-1965) have 5x higher rates
Cure rate:	Over 95% with direct-acting antiviral therapy

Symptoms

Most people with hepatitis C experience no symptoms initially. When symptoms do occur, they may include: fatigue, nausea, loss of appetite, muscle aches, jaundice, dark urine, and abdominal pain.

Acute hepatitis C symptoms (first 6 months after infection) affect only 20-30% of people and may include sudden onset of fatigue, nausea, vomiting, loss of appetite, low-grade fever, muscle and joint aches, and tenderness in the upper right abdomen. Jaundice (yellowing of skin and eyes) and dark-colored urine may develop but are relatively uncommon.

Chronic hepatitis C symptoms often don’t appear for 10-20 years. When they do occur, they typically indicate significant liver damage and may include persistent fatigue that interferes with daily activities, easy bruising and bleeding, fluid retention causing swelling in legs and abdomen, confusion and difficulty concentrating, and spider-like blood vessels on the skin.

Causes and risk factors

Hepatitis C is caused by infection with the hepatitis C virus, which spreads primarily through blood-to-blood contact. The virus has several genotypes, with genotype 1 being most common in North America and Europe.

High-risk factors include injection drug use (even once), blood transfusions or organ transplants before 1992, long-term kidney dialysis, being born to a mother with hepatitis C, and accidental needlestick injuries in healthcare settings.

Moderate-risk factors include having multiple sexual partners, having a sexual partner with hepatitis C, sharing personal items like razors or toothbrushes with infected individuals, and getting tattoos or piercings in unregulated settings.

Healthcare workers, people born between 1945-1965 (baby boomers), individuals with HIV, and those who have been incarcerated also face increased risk.

Prevention

Currently, no vaccine exists for hepatitis C, but the infection is highly preventable through risk reduction strategies. Primary prevention focuses on avoiding blood-to-blood contact with infected individuals.

Key prevention measures include never sharing needles, syringes, or drug preparation equipment; ensuring safe medical and dental procedures with sterile equipment; avoiding sharing personal items like razors, toothbrushes, or nail clippers; choosing licensed, regulated facilities for tattoos and piercings; and practicing safe sex, especially with multiple partners.

Screening recommendations include one-time testing for all adults aged 18-79, and testing for pregnant women during each pregnancy. High-risk individuals should undergo regular screening. Healthcare settings should implement universal precautions and safe injection practices.

Blood banks in developed countries have screened donations since 1992, virtually eliminating transfusion-related transmission. Harm reduction programs providing clean needles and opioid substitution therapy significantly reduce transmission among people who inject drugs.

Complications

Without treatment, chronic hepatitis C can lead to serious liver complications over 20-30 years. Approximately 20% of people develop cirrhosis (severe liver scarring), which can progress to liver failure requiring transplantation.

Major complications include liver cirrhosis, liver cancer (hepatocellular carcinoma), liver failure, portal hypertension leading to esophageal varices and internal bleeding, ascites (fluid accumulation in the abdomen), and hepatic encephalopathy (brain dysfunction due to liver failure).

Extrahepatic complications can affect other organ systems, including cryoglobulinemia (blood vessel inflammation), kidney disease, Type 2 diabetes, cardiovascular disease, and certain lymphomas. These complications occur because hepatitis C can affect immune function and cause chronic inflammation throughout the body.

The risk of complications increases with alcohol use, coinfection with hepatitis B or HIV, obesity, and older age at infection. Early treatment prevents most complications, emphasizing the importance of diagnosis and treatment.

Diagnosis

Hepatitis C diagnosis involves a two-step process: initial antibody screening followed by confirmatory RNA testing.

Initial screening uses the hepatitis C antibody test (anti-HCV), which detects antibodies the immune system produces in response to HCV infection. A positive result indicates current or past infection but cannot distinguish between the two.

Confirmatory testing includes HCV RNA testing (PCR) to detect active virus and determine viral load, and HCV genotype testing to identify the specific viral strain, which guides treatment selection.

Additional assessments include liver function tests (ALT, AST, bilirubin), complete blood count, liver biopsy or non-invasive fibrosis testing (FibroScan) to assess liver damage, and screening for hepatitis A, B, and HIV coinfection.

Monitoring tests during treatment include regular viral load measurements to assess treatment response, liver function monitoring, and complete blood counts to detect potential medication side effects.

Treatment

Modern hepatitis C treatment achieves cure rates exceeding 95% using direct-acting antiviral (DAA) medications. Treatment duration is typically 8-12 weeks for most patients.

First-line treatments include combination regimens such as sofosbuvir plus velpatasvir, glecaprevir plus pibrentasvir, and sofosbuvir plus velpatasvir plus voxilaprevir for treatment-experienced patients.

Treatment selection depends on HCV genotype, previous treatment history, presence of cirrhosis, and kidney function. Most modern regimens are effective against all genotypes (pan-genotypic).

Monitoring during treatment includes viral load testing at specific intervals and liver function monitoring. Side effects are generally mild and may include fatigue, headache, and nausea.

Treatment goals aim for sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after treatment completion, which represents a cure.

Prognosis

The prognosis for hepatitis C has dramatically improved with modern antiviral therapy. Over 95% of treated patients achieve sustained virologic response, effectively curing the infection.

With treatment: Patients who achieve SVR have excellent long-term outcomes, with significantly reduced risk of liver complications, liver cancer, and death. Even patients with advanced fibrosis or compensated cirrhosis benefit substantially from treatment, though they require continued monitoring for liver cancer.

Without treatment: Chronic hepatitis C follows a variable course. Approximately 15-25% of people clear the infection naturally, while 75-85% develop chronic infection. Of those with chronic infection, 10-20% develop cirrhosis over 20-30 years, and 1-5% annually develop liver cancer once cirrhosis is present.

Factors affecting prognosis include age at infection (younger patients have better outcomes), alcohol consumption (significantly worsens prognosis), coinfection with HIV or hepatitis B, obesity, and male gender.

Post-treatment, patients can be reinfected if exposed again, emphasizing the importance of continued risk reduction. Regular follow-up monitoring is recommended, especially for patients who had advanced fibrosis before treatment.

Quality of life

Living with hepatitis C, whether during chronic infection or after cure, requires attention to liver health and overall wellness.

Dietary recommendations include maintaining a balanced, nutritious diet, limiting alcohol consumption (complete avoidance is ideal), staying hydrated, and avoiding excessive iron supplements unless deficient. Patients with advanced liver disease may need dietary modifications including sodium restriction and protein management.

Exercise and activity: Regular moderate exercise is beneficial and safe for most patients. Those with advanced liver disease should consult their healthcare provider about activity limitations, particularly if portal hypertension is present.

Mental health support is important, as chronic illness can contribute to anxiety and depression. Many patients experience relief and improved mental health after successful treatment. Support groups and counseling can be valuable.

Workplace considerations may include fatigue management during treatment and addressing potential discrimination. Hepatitis C is not transmitted through casual contact, so workplace restrictions are generally unnecessary.

Social impacts: Education about transmission routes helps patients maintain relationships while protecting others. Open communication with family members and partners is important for both emotional support and prevention.

Pregnancy and fertility

Hepatitis C can affect pregnancy outcomes, though most women with hepatitis C have healthy pregnancies and babies.

Fertility impacts: Hepatitis C may slightly reduce fertility in both men and women, though most people with the infection can conceive successfully.

Pregnancy considerations: Mother-to-child transmission occurs in approximately 5% of pregnancies, with higher risk if the mother has high viral loads or HIV coinfection. Cesarean delivery does not reduce transmission risk. Breastfeeding is generally safe unless nipples are cracked or bleeding.

Treatment during pregnancy: Current direct-acting antiviral medications are not approved for use during pregnancy due to limited safety data. Treatment is typically deferred until after delivery and breastfeeding completion.

Monitoring: Pregnant women with hepatitis C require regular monitoring of liver function and viral load. Infants born to infected mothers should be tested for infection at 12-18 months of age.

Children

Pediatric hepatitis C is less common but requires specialized care and considerations.

Presentation in children: Most children with hepatitis C are asymptomatic and have normal growth and development. When symptoms occur, they may include fatigue, abdominal pain, and poor appetite.

Transmission: Most pediatric cases result from mother-to-child transmission. Other routes include blood transfusions before 1992, unsafe medical procedures, or household transmission through shared personal items.

Treatment considerations: Several direct-acting antiviral medications are now approved for children as young as 3 years old. Treatment decisions consider the child’s age, weight, genotype, and family circumstances.

School accommodations: Children with hepatitis C typically don’t need special accommodations, as the virus isn’t transmitted through casual contact. Schools should follow standard precautions for blood exposure.

Transition to adult care: Adolescents require careful transition planning to ensure continued monitoring and treatment adherence in adult healthcare systems.

When to see a doctor

Seek immediate medical attention for symptoms suggesting acute liver failure: yellowing of skin or eyes, severe abdominal pain, persistent vomiting, confusion or altered mental state, easy bruising or bleeding, or dark urine with pale stools.

Schedule routine evaluation if you have risk factors for hepatitis C, including any history of injection drug use, blood transfusion before 1992, being born between 1945-1965, healthcare work with blood exposure, or sexual contact with someone who has hepatitis C.

Follow-up care is essential for diagnosed patients, including regular monitoring during treatment, post-treatment follow-up to confirm cure, and long-term surveillance for patients who had advanced liver disease.

Prevention counseling should be sought by individuals at high risk for exposure, including people who inject drugs, healthcare workers, and those with multiple sexual partners.

Regional context

Limited specific data exists for hepatitis C prevalence in the Caucasus region, though injection drug use and healthcare-related transmission have been identified as concerns in some areas. Regional healthcare systems are working to improve screening and treatment access, particularly in rural areas where specialist care may be limited.

GMJ welcomes contributions from regional researchers to build the evidence base for hepatitis C in the Caucasus, particularly regarding genotype distribution, treatment outcomes, and healthcare delivery models appropriate for the region.

Research and clinical trials

Current hepatitis C research focuses on simplified treatment regimens, shorter duration therapy, and improved access to care globally. Studies are investigating pan-genotypic treatments that don’t require genotype testing, ultra-short treatment courses, and combination prevention strategies.

Emerging areas include research into preventing reinfection, treating patients with severe kidney disease, and developing strategies for micro-elimination in specific populations.

Vaccine development continues, though challenges include the virus’s genetic variability and unclear correlates of protective immunity.

Clinical trials are available through ClinicalTrials.gov, particularly for patients with treatment failure, unusual genotypes, or specific comorbidities.

Frequently asked questions

Can hepatitis C be completely cured?

Yes, modern direct-acting antiviral medications cure over 95% of patients with hepatitis C. A cure is defined as having no detectable virus 12 weeks after completing treatment.

How is hepatitis C transmitted?

Hepatitis C spreads primarily through blood-to-blood contact. The most common route today is sharing needles for injection drug use. It’s not transmitted through casual contact, sharing food, or hugging.

Do I need treatment if I feel fine?

Yes, hepatitis C can cause serious liver damage over time even without symptoms. Early treatment prevents complications and cures the infection with minimal side effects.

Can I get hepatitis C again after being cured?

Yes, reinfection is possible if you’re exposed to the virus again after cure. The treatment doesn’t provide immunity, so continued risk reduction is important.

Is hepatitis C treatment covered by insurance?

Most insurance plans cover hepatitis C treatment, though prior authorization may be required. Patient assistance programs are available for uninsured individuals.

Support and resources

International organizations:
– World Health Organization (WHO) Hepatitis Program: who.int/health-topics/hepatitis
– Hepatitis C Trust: hepctrust.org.uk
– American Liver Foundation: liverfoundation.org
– European Association for the Study of the Liver (EASL): easl.eu

Patient support:
– HepC Connection: hepcconnection.org
– National Viral Hepatitis Roundtable: nvhr.org
– Liver Health Connection: liverhealthconnection.org

Healthcare provider resources:
– HCV Guidance Panel: hcvguidelines.org
– CDC Viral Hepatitis Resources: cdc.gov/hepatitis

Related conditions

Hepatitis B – Another viral liver infection with similar transmission routes but different treatment approaches and the availability of effective vaccination.

Hepatitis A – An acute viral liver infection spread through contaminated food and water, preventable with vaccination.

Liver Cirrhosis – Advanced scarring of the liver that can result from chronic hepatitis C infection, leading to liver failure and other complications.

Hepatocellular Carcinoma – Primary liver cancer that can develop in patients with chronic hepat

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.